Zobel EH, et al. - Since several new antihyperglycaemic drugs in type 2 diabetes have pleiotropic effects in favor of cardiovascular and renal risk, researchers via performing a secondary analysis of the LIRA-RENAL trial studied individual responses to liraglutide in six cardio-renal risk factors (HbA1c, body weight, systolic blood pressure [SBP], low density lipoprotein [LDL]-cholesterol, urine albumin-to-creatinine ratio [UACR] and estimated glomerular filtration rate [eGFR]) in order to determine responses to one risk factor are correlated with changes in other risk factors (cross-dependency). Of the 279 participants exposed to study drugs, 220 participants were included who had at least one of the six variables measured at baseline and after 26 weeks of treatment with liraglutide or placebo. Findings suggested that treatment with liraglutide has pleiotropic effects that change cardiovascular and renal risk favorably. Investigators observed that the treatment response to liraglutide is largely individual and, in addition to the association between reducing body weight and reducing HbA1c, there are no clear cross-dependence in the response to the risk factor. Patients treated with placebo did not see the same association.